Genetic contribution of catechol-O-methyltransferase variants in treatment outcome of low back pain: a prospective genetic association study by Ahmad Omair et al.
Omair et al. BMC Musculoskeletal Disorders 2012, 13:76
http://www.biomedcentral.com/1471-2474/13/76RESEARCH ARTICLE Open AccessGenetic contribution of catechol-O-
methyltransferase variants in treatment outcome
of low back pain: a prospective genetic
association study
Ahmad Omair1,4*, Benedicte Alexandra Lie2, Olav Reikeras1, Marit Holden3 and Jens Ivar Brox1Abstract
Background: Treatment outcome of low back pain (LBP) is associated with inter-individual variations in pain relief
and functional disability. Genetic variants of catechol-O-methyltransferase (COMT) gene have previously been shown
to be associated with pain sensitivity and pain medication. This study examines the association between COMT
polymorphisms and 7–11 year change in Oswestry Disability Index (ODI) and Visual Analog Score (VAS) for LBP as
clinical outcome variables in patients treated with surgical instrumented lumbar fusion or cognitive intervention
and exercise.
Methods: 93 unrelated patients with chronic LBP for duration of >1 year and lumbar disc degeneration (LDD) were
treated with lumbar fusion (N= 60) or cognitive therapy and exercises (N= 33). Standardised questionnaires
assessing the ODI, VAS LBP, psychological factors and use of analgesics, were answered by patients both at baseline
and at 7–11 years follow-up. Four SNPs in the COMT gene were successfully genotyped. Single marker as well as
haplotype association with change in ODI and VAS LBP, were analyzed using Haploview, linear regression and
R-package Haplostats. P-values were not formally corrected for multiple testing as this was an explorative study.
Results: Association analysis of individual SNPs adjusted for covariates revealed association of rs4633 and rs4680
with post treatment improvement in VAS LBP (p= 0.02, mean difference (β)= 13.5 and p= 0.02, β= 14.2
respectively). SNPs, rs4633 and rs4680 were found to be genotypically similar and in strong linkage disequilibrium
(LD). A significant association was found with covariates, analgesics (p= 0.001, β= 18.6); anxiety and depression
(p= 0.008, β= 15.4) and age (p= 0.03, mean difference per year (β)= 0.7) at follow-up. There was a tendency for
better improvement among heterozygous patients compared to the homozygous. No association was observed for
the analysis of the common haplotypes, these SNPs were situated on.
Conclusions: Results suggest an influence of genetic variants of COMT gene in describing the variation in pain
after treatment for low back pain. Replication in large samples with testing for other pain related genes is
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Lumbar disc degeneration (LDD) represents a cause of
the low back pain (LBP) [1]. A strong correlation be-
tween the severity of degeneration and LBP has not been
established. Some studies have found a relationship be-
tween the radiological findings of LDD and LBP [2],
while others indicate a high prevalence of abnormal
radiological changes in asymptomatic individuals [3,4].
A substantial inter-individual variation among LDD
patients with regard to the pain sensitivity and the re-
quirement of post-operative analgesia has been recog-
nized. Thirty five to 68 percent of the LBP susceptibi-
lity has been reported to be accounted for by the genetic
factors [5].
Variation in certain genes encoding proteins involved
in pain modulation, transduction, transmission, and con-
duction pathways (pain-genes), could be helpful in clas-
sifying the LDD patients experiencing varying degrees of
pain. With regard to the variation in human pain pheno-
types, associations have been reported with single nu-
cleotide polymorphisms (SNPs) in genes coding for
catechol-O-methyltransferase (COMT), opioid receptors
(OPRM1, OPRD1), transient receptor potential (TRPV1,
TRPA1), fatty acid amide hydrolase (FAAH) and α-subunit
of voltage gated sodium channel (SCN9A)[6-11].
Among these, COMT gene variations (more than 30
SNPs) are the most studied in both human and ex-
perimental models.
COMT is an enzyme that mediates the O-methylation
of certain catecholic pain pathway neurotransmitters in-
cluding catecholamines (adrenaline and noradrenaline),
dopamine, catecholestrogens and their hydroxylated
metabolites [12-14], thereby eliminating their biological
activity and toxicity. COMT is highly expressed in liver,
kidney, brain, adrenal and lungs [15]. Although the
exact mechanism is unclear, it has been proposed
that it acts by effecting the adrenergic, noradrenergic
and dopaminergic pain modulating and processing
mechanisms [16,17].
The COMT gene is located on chromosome 22q11.2
[18]; with a 1.3 kb transcript producing the low affinity
soluble S-COMT and a 1.5 kb transcript producing both
soluble and high affinity membrane bound MB-COMT
[15]. Polymorphisms of the COMT gene have been
shown to contribute to the inter-individual variations in
sensitivity, severity and chronicity of pain as well as its
response to analgesics [8,19]. Pain intensity is also influ-
enced by psychological factors and use of pain medica-
tion. Anxiety and depression are often associated with
chronic pain [20].
The most studied COMT SNP (rs4680. Val158Met)
is located in the coding region, where a non-
synonymous A to G single nucleotide change causes
replacement of valine (Val) to methionine (Met) atcodon 158 in MB-COMT and 108 in S-COMT [21].
Met158 has lower thermo-stability and hence a
decreased enzyme activity at normal body temperature
as compared to the Val158 [22]. With regard to the
genotypes, it has been shown that Val158 homozygous
individuals have three-fourfold increased activity of
COMT compared to the Met158 homozygotes, and an
intermediate COMT activity with heterozygotes [23].
The COMT activity showed an inverse correlation
with pain sensitivity. It has also been reported that in
response to muscular pain, individuals homozygous
for the 158Met allele possessed decreased activation
and higher density of μ-opioid receptors in brain com-
pared to 158Val homozygotes [24]. In another study in-
volving cancer pain patients, it was reported that 158Val
homozygotes required a 50% higher morphine dose than
the 158Met homozygotes in [25].
An allele at another coding COMT polymorphism
rs6267, also encodes a substantially less active enzyme
but its prevalence is much lower [26]. In the non-coding
region of the COMT gene, rs2075507 has been shown to
impart a minor effect on the enzyme activity through
altering mRNA expression [27].
A recent study found an association of a COMT SNP
rs4633, as well as of a haplotype containing rs4633,
rs4680, rs6269 and rs4818 with greater improvement in
1 year post-operative Oswestry Disability Index (ODI)
score in patients who had fusion for persistent LBP [28].
On the basis of variation in experimental pain sensi-
tivity; a study has identified a high pain sensitivity
(HPS) or low COMT activity haplotype, a low pain sen-
sitivity (LPS) or higher COMT activity haplotype, both
including the similar amino acid sequence of Val158Met
polymorphisms and differing in a synonymous SNP [8].
The APS/HPS diplotype causing the low COMT activity
was also found to be associated with higher pre-
operative pain scores and increased risk for post-
operative pain [29].
In light of the broad spectrum of pain ratings in
patients with LDD treated for LBP, we aimed to investi-
gate the effect of the genetic variation in COMT gene on
the pain and disability scores among patients treated
with lumbar instrumental fusion or cognitive interven-
tion and exercises.Methods
Study design
This study is a prospective genetic association study.
The cohort used was originally designed as a rando-
mized control trial and the prospective design was used
for obtaining data at follow up but results are given for
the whole cohort with adjustment for the treatment
received.
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124 unrelated Norwegian patients with chronic LBP and
age ranging from 25–60 years, who were recruited from
two randomized control trials (RCTs) published previ-
ously, were invited to participate. Results from the two
RCTs showed no difference among groups randomized
to surgical and cognitive intervention and exercises and
the studies were merged at long term follow-up [30-33].
At baseline, each patient was examined by at least one
spine surgeon and one specialist in physical and rehabili-
tation medicine. All patients underwent plain radiog-
raphy of lumbar spine. The inclusion criteria were:
age ≥ 25 years; LBP, duration >1 year despite of undergo-
ing supervised non operative treatment; ODI score > 30
of 100 points; and disc degeneration at no more than
two levels i.e. L4-L5 and/or L5-S1 as assessed by
plain radiography. Exclusion criteria were: widespread
myofascial pain; spinal stenosis with reduced walking dis-
tance and associated neurological signs; recurrent disc
herniation or lateral recess stenosis with clinical signs of
rediculopathy; inflammatory disease; previous spinal frac-
ture; previous surgical fusion of spine; pelvic pain; general-
ized disc degeneration on plain radiographic assessment;
ongoing serious somatic or psychiatric disease that could
exclude treatment alternatives; registered medical abuse
and reluctance in accepting either one or both treatment
modalities of this study.
Ninety nine patients responded to the follow-up exam-
ination at mean 8.5 years (range 7–11 years). Ninety three
patients were ethnically West European and hence 6 were
excluded due to a non European ethnicity. Fifty one were
randomized to lumbar instrumented fusion and 42 to cog-
nitive intervention and exercises. Five patients randomized
to fusion did not undergo surgery and 14 patients rando-
mized to cognitive treatment had later undergone fusion.











Change in VAS LBP
Percentage patients taking daily analgesics at follow-up
Percentage patients reported moderate to severe anxiety and depression atwith LBP, according to the treatment received are given in
Table 1. Among the 19 patients who did not receive the
treatment they were randomized to, 7 were males and 12
were females, mean age was 53.5 years and ODI and VAS
LBP change given as mean [SD] were – 22.6 [24.8]
and – 26.3 [30.0] respectively.
The eligible patients were informed orally as well as in
writing about the study procedures before consenting.
The Regional Committee for Medical Research Ethics
in Health Region South-East Norway approved the
study. It was also recommended by Biobank register
at the Norwegian Institute of Public Health and by
patient’s ombudsman at Oslo University Hospital.
Study interventions
The surgery was postero-lateral fusion with transpendi-
cular screws at L4-L5 and /or L5-S1. Cognitive interven-
tion and exercises were given by physiotherapists and a
specialist in physical and rehabilitation medicine, and
involved one week plus two weeks at outpatient facility
interrupted by two weeks at home.
Predictors and outcome variables
The clinical data regarding age, ethnicity, gender, and
co-morbidity was obtained at baseline. At baseline and
follow-up, these patients filled in standardised question-
naires for assessing the ODI and VAS (Visual Analog
Scale) LBP scores. ODI comprised of 10 questions about
pain and pain related disability, each having six verbal
response alternatives. The sum of the response score is
calculated and presented as percentage where 0% repre-
sents no pain and disability, and 100% represents the
worst possible pain and disability [34].
Low back pain intensity was scored on three vertical
visual analog scales, ranging from 0 (no pain) to 100




52.3 [8.0] 51.1 [8.0]
46.0 [11.8] 40.6 [8.5]
23.8 [18.6] 24.6 [15.9]
- 22.2 [23.0] −16 [15.4]
63.4 [14.6] 60.6 [11.6]
35.6 [27.0] 41.8 [22.1]
- 27.8 [29.2] −18.8 [23.2]
51 24
follow-up 31 35
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spectively. The mean of these three measurements was
calculated [35].
Information on the use of analgesics was reported by
patients as four response alternatives: daily; weekly;
monthly and less often [36]. Pain medication was
dichotomized into using daily pain medication and less
often.
Information on anxiety and depression was acquired
through EuroQol questionnaire EQ-5D [37,38] and Hop-
kins Symptom Check List (HSCL-25) [39]. These vari-
ables were correlated (r= 0.7). In the present study we
used the domain from EQ-5D, dichotomized into no
anxiety and depression and moderate to severe anxiety
and depression.
Clinical outcome variables used were the change in
ODI and VAS LBP scores from baseline to 7–11 year
follow-up (post treatment value – pre treatment value),
that is the change for the whole cohort overtime and not
the difference in change between treatment groups.
Genotyping
Genomic DNA from 87 patients was extracted from 9 ml
of venous blood by salting out method [40] and for the
remaining 6 patients from 2 ml of saliva using a collection
kit (DNA genotek, kanata, Ontario Canada). Based on the
previously proposed association between genetic variations
of catechol-O-methyltransferase (COMT) and difference in
pain sensitivity, five SNPs (rs4633, rs4680, rs4818, rs6269
and rs2097603) were selected for genotyping [28]. Genotyp-
ing for these SNPs was performed by SequenomTM system,
using matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry at the Centre for
interactive genetics; Cigene, Norwegian University of Life
Sciences (UMB) Aas.
Statistical Analysis
Hardy-Weinberg equilibrium, pair wise linkage dis-
equilibrium (LD), genotype success rate and minor
allele frequency were calculated using the statistical
programme Haploview version 4.2 [41]. The cut off
value for divergence from Hardy-Weinberg equilib-
rium was (p ≥ 0.001). Inclusion of SNPs in this study
was subject to the threshold for genotype success rate
(GSR) set to be > 95%.
Linear regression analysis was performed for assessing
the effect of each individual SNP on the ODI and VAS
LBP change as dependent variables, along with control-
ling for covariates such as age, gender, fusion, analgesics
and psychological factors. Normality was tested by histo-
grams and Q-Q plots of residuals and was found to be
acceptable for regression analysis.
Analysis was performed by using both recessive and
additive genetic models. In the recessive model, weassumed that the change in post treatment pain scores
was increased / decreased when having two copies of a
specific allele compared to having only one or zero cop-
ies of the specific allele. Mean difference in pain score
(β) between patients having two copies and those having
one or zero copies was estimated in regression analysis.
In the additive model, we assumed that the change in
the post treatment pain scores was increased two fold by
possessing two copies of the specific allele, compared to
having a single copy. A p-value ≤0.05 was considered
statistically significant. This was an explorative study
and therefore the p-values were not formally corrected
for multiple testing. The effect size for power 0.8 and
significance level of 0.05 for rs4633 and rs4680 was 0.65
and a conservative estimate for smallest difference for
VAS LBP change was calculated to be 17.4.
Association analysis between the common haplotypes
of the SNPs with frequency > 0.02 and ODI and VAS
LBP change, along with effect of covariates was per-
formed on data from the whole cohort of 93 patients
using the R package Haplostats [42]. The estimated
frequencies and regression coefficients were computed
by the function haplo.glm using an additive model by
default. The reference haplotype was selected to be the
most frequent haplotype as a baseline for linear regres-
sion by the software.
Results
The genotype success rate was≥ 97% for all SNPs
(Table 2), except rs2097603 (71%), which was therefore
excluded. No divergence from Hardy-Weinberg equilib-
rium was observed for any of the tested markers
(Table 2). The minor allele frequencies observed for each
SNP in our population were comparable to what has
been reported for European Hap Map samples (Table 2).
Single marker association analysis
In order to test an association of individual SNPs with
the 7–11 years change in ODI and VAS LBP scores, a re-
cessive genetic model was used in addition to the addi-
tive genetic model due to the restricted power of our
sample. In the presence of age, gender and fusion as cov-
ariates, recessive model analysis of 93 patients (both
surgical and cognitive-exercise) revealed associations
between COMT polymorphisms rs4633 and rs4680 and
post treatment reduction in pain (p=0.05, β=12.1 and
p=0.04, β=12.7 respectively). These covariates were
found to be non significant. No association was observed
for the remaining two SNPs.
The association between rs4633 and rs4680 and reduc-
tion in pain was statistically significant (p= 0.02) after
adjustment for consumption of analgesics, and anxiety
and depression. These covariates were found to be sig-
nificantly associated with reduction in pain (Table 3).
Table 2 Overview of the selected COMT SNPs
SNP* Location HWE** p-val GSR %† Alleles { MAF} cases MAF reported
rs4633 Exon 3 0.92 97.8 C/T 0.46 0.52
rs4680 Exon 4 1.0 100 G/A 0.46 0.52
rs4818 Exon 4 1.0 100 G/C 0.41 0.48
rs6269 Intron 2 0.91 100 G/A 0.42 0.49
* Single nucleotide polymorphism; ** Hardy-Weinberg equilibrium; † Genotype success rate;
{ Minor/Major alleles; } Minor allele frequency.
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reported to take analgesics weekly or less often at
follow-up and in patients who reported no anxiety and
depression at follow-up. SNPs explained 3% of the vari-
ation and 11% with age, gender and fusion. When
analgesics and anxiety and depression were entered into
the model, the explained variance increased from 11 to
31%. No association was observed for any of the SNPs
with ODI change, although the ODI change explained
60% of variance in pain change.
A sensitivity analysis performed according to intention
to treat, revealed associations similar to the analysis
based on treatment received. In the additive genetic
model we observed no significant association between
the tested markers and the follow-up ODI and VAS LBP
change.
The two polymorphisms rs4680 and rs4633 were in
strong linkage disequilibrium [LD] (D'= 1 and r2= 1) and
hence A/A, A/G and G/G of rs4680 corresponded to the
T/T, T/C and C/C of rs4633. Among the total group of
93 patients, two patients lacked rs4633 data while none
lacked results for rs4680. Therefore, as these two SNPs
were perfectly correlated (r2= 1), we chose to focus on
rs4680 in further analysis. We observed that patients
heterozygous for rs4680 alleles had a greater improve-
ment in pain at long term follow-up (Figures 1 and 2).
The reduction in pain (given as mean [SD] of change
in VAS LBP score) was largest among A/G heterozygotes
(−32.2 [25.4]), followed by a nearly equal reduction
among A/A homozygotes (−17.5 [25.3]) and G/G
homozygotes (− 16.7 [31.0]) (Table 4).Table 3 Single marker association analysis of COMT SNPs and
recessive genetic model
rs4633
Mean difference (β)† (95% CI)
SNP*} 13.5 (1.9, 25.0)
Age 0.7 (0.05, 1.3)
Gender 6.9 (−3.9, 17.7)
Fusion 11.82 (0.8, 22.8)
Analgesics 18.4 (7.2, 29.6)
Anxiety and depression 14.6 (3.2, 26.0)
* Single nucleotide polymorphism, † mean difference in pain score (for age β is the
rs4680: A/A).Associations for rs4633 and rs4680 with improve-
ment in pain among the fused group were also statis-
tically significant, both in the absence and when
controlled for covariates.
Haplotype association analysis
In view of the previously proposed associations of differ-
ent COMT haplotypes with pain sensitivity and the fact
that more haplotypes have shown associations compared
to the individual SNPs, we constructed haplotypes. All
four SNPs were in strong LD, and the three most com-
mon haplotypes accounted for more than 96.6% of all
observed haplotypes (Table 5). No association was
observed for any of the haplotypes, with reduction in
pain and disability at long term.
Discussion
In the present study we found significant associa-
tions between the COMT polymorphisms rs4633 and
rs4680 (Val158Met) and pain reduction at long term
follow-up among fused and non-fused patients with
chronic LBP. The polymorphism rs4633 was in
complete linkage disequilibrium (LD) with rs4680
and hence showed similar results.
Dai et al were the first to test the association between
COMT variants and surgical outcome with regard to pain
and disability in 69 patients with lumbar fusion. They
reported an association between improvement in ODI
score and both a single marker (rs4633) and a COMT
haplotype [28]. Our results are in line with Dai et al. with
regard to the associations observed between success7–11 years follow-up VAS LBP change in 93 patients, a
rs4680
p value Mean difference (β) (95% CI) p value
0.02 14.2 (2.7, 25.6) 0.02
0.04 0.7 (0.08, 1.4) 0.03
0.21 7.8 (−2.8, 18.5) 0.15
0.04 10.9 (0.1, 21.6) 0.05
0.002 18.6 (7.5, 29.7) 0.001
0.01 15.4 (4.1, 26.7) 0.008
mean difference in pain score per year); } Recessive genotype (rs4633: T/T;
Figure 1 Bar plot diagram of 93 patients for post treatment
VAS LBP change. Bar plot diagram of 93 patients for post
treatment VAS LBP change (given as mean) in three genotypes (A/A,
A/G, G/G) of rs4680. The error bar denotes the standard error of the
mean; N denotes the number of patients for each genotype and the
height of the filled rectangle boxes denotes the mean.
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findings, as our associations were with pain reduction
and not with ODI. In addition we reported associ-
ation for rs4680 as well, which was not found in the
study by Dai et al.Figure 2 Scatter plot diagram of 93 patients for post treatment VAS L
change in three genotypes (A/A, A/G, G/G) of rs4680. The dashed line represenAlthough the pain genes could only explain 3.0% of the
variance in pain change, association remained significant
after adjustment for covariates. The most important cov-
ariates were the reported use of pain medication and anx-
iety and depression at follow-up, as the explained variance
increased from about 11% for the pain gene with age, gen-
der and treatment to about 31% with addition of pain
medication and anxiety and depression. Twice as many
fused patients (51%) used analgesics daily at follow up,
compared with the cognitive intervention and exercises
(24%) and although the co linearity and correlation statis-
tics was acceptable for performing multiple regression
analysis, fusion was both negatively (with pain medication)
and positively associated with change in pain (Table 3).
The observed associations suggest that it seems unlikely
that treatment responses can be predicted solely by the
analysis of COMT gene polymorphisms and it may be
recommended to assess the influence of candidate genes
for both disc degeneration and pain in a larger cohort.
In the present study the largest improvement was
observed for A/G heterozygous patients using the reces-
sive genetic model. These results are contrary to the
dose effect of the SNP and along with lack of association
observed in the additive model, suggest that the effect is
not increasing. Studies have shown that the three geno-
types of the rs4680 influence the human experience of
pain differently, with Met/Met homozygous patients
being more pain sensitive compared to the Val/Val and
those heterozygous possessed an intermediate pain sen-
sitivity [24]. Increased enzyme activity is inversely
related with the pain sensitivity and it has been reportedBP change. Scattergram of 93 patients for post treatment VAS LBP
ts the mean value and continuous lines denote standard error of mean.
Table 4 Characteristics of the patients (N= 93) after
stratification on rs4680 genotypes (Mean [SD])
Variable A/A A/G G/G
No of patients 27 46 20
Gender (M / F) 6 / 21 18 / 28 11 / 9
Age at follow-up 51.8 [8.3] 52.0 [8.2] 51.7 [7.3]
Fusion / Cognitive 19 / 8 30 / 16 11 / 9
Baseline ODI 43.7 [10.2] 46.1 [11.9] 39.9 [9.2]
Follow-up ODI 26.1 [17.4] 22.1 [19.7] 25.8 [18.1]
ODI change - 17.6 [17.0] - 24.0 [22.6] - 14.1 [19.7]
Baseline VAS LBP 59.9 [14.1] 64.4 [13.4] 61.3 [13.6]
Follow-up VAS LBP 42.5 [18.3] 32.1 [26.6] 44.6 [29.0]
VAS LBP change - 17.5 [25.3] - 32.2 [25.4] - 16.7 [31.0]
VAS LBP change [Median] - 19.3 - 24.7 - 4.3
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and vice versa, while the heterozygotes express an inter-
mediate COMT activity [14]. Lotsch et al. reported that
carriers of Val/Val alleles were more sensitive to pain
compared to the non carriers [43]. The present findings
of a larger pain reduction in heterozygous individuals
after stratification according to genotypes, does not fit
with the already reported results. Frequency of Val/Met
heterozygotes was much higher in our sample compared
to Val/Val and Met/Met homozygotes. Due to a small
sample size the findings could be false and by chance as
we have not observed pain improvement in homozygous
individuals which should have been in line with assumed
functional effect of the enzyme. A case control study
involving 61 Turkish fibromyalgia patients has previ-
ously reported a higher frequency of Val/Met heterozy-
gotes [44] and also an association between individuals
heterozygous for COMT gene polymorphisms rs464312
and rs6269 and pain sensitivity has previously been
reported [10].
The association observed in the present study was with
change in pain scores at long term follow-up, while Dai et
al. have assessed the change at 1 year and in contrast to
our findings Dai et al. reported a greater improvement
with rs4633 homozygotes and an intermediate improve-
ment with heterozygotes. In the present study change in
ODI and VAS LBP were moderately correlated (r2=0.6)
and therefore it is not unlikely to detect an association
with one variable and not with the other. Contrary toTable 5 Observed haplotypes and their estimated
frequencies
rs4633 rs4680 rs4818 rs6269 Frequency %
T A C A 52.7
C G G G 40.1
C G C A 3.8Dai et al. who reported a significant association between
a haplotype involving rs4633, rs4680, rs6269 and rs4818
and greater improvement in ODI score, our associations
for similar haplotypes did not reach statistical signifi-
cance neither for ODI nor for pain change. This is des-
pite the fact that we have found association for two
individual SNPs i.e. rs4680 and rs4633, which were also
a part of this haplotype. Diatchenko L et al have also
reported that as a single SNP, rs4680 was not associated
with pain sensitivity despite possessing the same amino
acid sequence as part of different haplotypes possessing
different COMT activity and pain sensitivities [8]. These
minor discrepancies could be due to population differ-
ences in LD and haplotype structures. The contrasting
results make it difficult to establish the true genotypic
effect. Nevertheless both these studies support the poly-
morphism as being associated. Genetic studies ideally
require a large patient number that can tolerate the
correction for multiple testing in order to avoid false
positive results. Patient sample of the present study is
larger as compared to Dai et al. and included fused and
non-fused patients.
The mechanism of pain modulation is complex and
many studies have either failed to show any associations
between COMT variation and pain sensitivity [45,46],
while other studies have found an association with pain
sensitivity and variation in dosage requirement of mor-
phine in cancer pain patients [25].
Inclusion of covariates in the analysis and homogeneity
with regard to genetic make up and ethnicity are the
strengths of this study. The distribution of different geno-
types of rs4680 (A/A, A/G and G/G) was homogenous
among both surgical and cognitive-exercise group (p=0.6),
and hence there was no evidence for selection bias on the
basis of genetic make up among patients treated by the
two different modules.
The conservative estimate for smallest difference for
VAS LBP change was set at 17.4 in this study. Despite
having limitations of sample size and being underpow-
ered, this study gives suggestion towards the direction in
which future research should head in examining the dif-
ferent clinical phenotypes related to patients with lum-
bar disc degeneration.
LBP is a major cause of disability among the popula-
tion of the industrialized world, in turn leading to a
socio-economic deterioration [47]. The pathogenesis and
etiology of lumbar disc degeneration is complex regard-
ing both degenerative process and patient’s symptom-
atology with regard to pain and disability. Radiologically
assessed changes in the discs may or may not cause pain
[48] and there is a visible variation in the patient out-
comes after treatment. Thus, there is an indication and
need for spine researchers to expand their knowledge at
the molecular level, with regard to genetics of the
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difference in pain sensitivity following the treatments.
Co-morbidity in patients with LBP has also been
reported. Hagen et al, reported that pain was more often
located to the whole spine (not just the lower back), legs
and head, in patients with LBP as compared to the normal
healthy controls [49]. Another study reported an increased
prevalence of subjective health complaints in patients suf-
fering from sciatica due to a herniated disc, compared to
the normal healthy population [50]. These findings suggest
a role of underlying genetic factors related to the pain sen-
sitivity and perception that can predispose the patient to
chronic pain, not just in the lower back but in other parts
of the body as well. Previous studies have focussed on disc
degeneration and genetics to reveal spine specific risk fac-
tors, while the focus on the role of pain genetics in the
clinical outcome of LBP patients has been lacking.
Conclusions
This study reports an association between variation in
the pain gene COMT and reduction in pain in patients
with LBP and lumbar disc degeneration at long term fol-
low-up. Our findings suggest that genetic variants of
COMT gene may contribute to describe the success of
treatment, but that psychosocial factors might be more
important. These results warrant replication in large
samples with testing for other pain related genes, which
in turn may help explain the inter-individual variation
and contribute to more predictable treatment outcome.Abbreviations
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